The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 17, 2015

Filed:

Jul. 03, 2013
Applicant:

Abbott Laboratories, Abbott Park, IL (US);

Inventors:

John L. Toner, Libertyville, IL (US);

Sandra E. Burke, Libertyville, IL (US);

Keith R. Cromack, Gurnee, IL (US);

Randolf von Oepen, Los Altos Hills, CA (US);

Assignee:

Abbott Laboratories, Abbott Park, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61F 13/00 (2006.01); A61L 31/16 (2006.01); A61F 2/91 (2013.01); A61F 2/958 (2013.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61L 31/10 (2006.01);
U.S. Cl.
CPC ...
A61L 31/16 (2013.01); A61F 2/91 (2013.01); A61F 2/958 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61L 31/10 (2013.01); A61F 2250/0067 (2013.01); A61F 2310/0097 (2013.01); A61L 2300/606 (2013.01);
Abstract

System for treating vascular disease comprising a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state, a coating disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of Zotarolimus (ABT578), everolimus, pimecrolimus, and a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall, and further wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent on the outer surface remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall, and optionally, a stent disposed on the balloon.


Find Patent Forward Citations

Loading…